Molecule intelOpportunity: Lower0

Strontium Ranelate

15 brands · 15 companies · product forms

Opportunity snapshot

Launch attractiveness
13
Market saturation
38
Price room
3
Regulatory risk
0
15
brands
15
companies
Rs 200
median price
3
price points
1.14x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 7%

Price room

Across observed sources and strengths
CheapestRs 175
MedianRs 200
Most expensiveRs 200
Spread1.14×
Sources: DVAGO

max/min price ratio 1.14x across 3 trusted points (Rs 175.0-200.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 3 live products for Strontium Ranelate — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(3) + 20% low-competition(62) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

15 canonical companies and 15 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 1.14x across 3 trusted points (Rs 175.0-200.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.